Andrew Goldman is a Senior Advisor consulting with the Medicines Patent Pool (MPP).
MPP is a UN-backed non-governmental organisation working to increase access to affordable medical technologies in low- and middle-income countries through the use of voluntary licensing and technology transfer.
Andrew specifically focuses on MPP’s “upstream access” workstream, where he works with universities, research institutes, and funders on how to incorporate conditions into licensing and funding agreements for early-stage technologies that can facilitate equitable access to medical technologies once the technologies are commercialized. Andrew was previously on the legal team for MPP in Geneva where he worked on public health-oriented voluntary licensing of medical technologies across a variety of disease fields, and Andrew has additionally worked for for-profit companies as well as civil society organizations on legal and policy issues relating to access to medical technologies. Andrew received his B.A. from Princeton University, his M.A. from Columbia University, and his J.D. from the University of Maryland School of Law. He lives in Washington DC.